Evidence map›Paper›PMID 41273779›Full record

ReviewThe oncologist2025

Clinical characteristics of the ALK fusion-positive bladder PMP and efficacy of lorlatinib: a two-case report and literature review.

Meng Sun, Mengyang Ju, Hao Zhang, Ning Huang, Sheng Zhang, Mingjuan Sun

Erratum issuedAbstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Meng SunDepartment of Biochemistry and Molecular Biology, School of Basic Medical Science, Naval Medical University, Shanghai 200433, China.
Mengyang JuShanghai Cancer Center and Shanghai Medical College, Fudan University, Shanghai 200032, China.
Hao ZhangDepartment of Biochemistry and Molecular Biology, School of Basic Medical Science, Naval Medical University, Shanghai 200433, China.
Ning HuangDepartment of Biochemistry and Molecular Biology, School of Basic Medical Science, Naval Medical University, Shanghai 200433, China.
Sheng ZhangShanghai Cancer Center and Shanghai Medical College, Fudan University, Shanghai 200032, China.ORCID 0000-0002-0109-6951
Mingjuan SunDepartment of Biochemistry and Molecular Biology, School of Basic Medical Science, Naval Medical University, Shanghai 200433, China.ORCID 0009-0004-9185-4024

Funding

National Key Research and Development Program 2019YFC0312603Naval Medical University 2024MS001
6 · The paper itself

Abstract

Pseudosarcomatous myofibroblastic proliferation (PMP) is a rare anaplastic lymphoma kinase (ALK), ALK fusion-associated tumor-like lesion that requires differentiation from inflammatory myofibroblastic tumor (IMT). This article reports two cases of bladder ALK fusion-positive PMP: a 16-year-old male achieved partial remission (PR) postoperatively with lorlatinib but experienced memory decline and mood disturbances, which resolved after dose reduction; a 34-year-old female showed significant tumor shrinkage (PR) without severe adverse reactions. The study confirms the marked efficacy of ALK inhibitors in ALK-positive PMP, but highlights the need to monitor neurotoxicity in adolescent patients. Through analysis of the FN1 (Fibronectin 1)-ALK fusion mechanism and literature review, this study emphasizes the importance of pathological differentiation, individualized treatment, and dynamic cognitive monitoring, providing insights for precision therapy in rare diseases.

Indexed as

AminopyridinesAnaplastic Lymphoma KinaseLactamsLactams, MacrocyclicUrinary Bladder NeoplasmsAdolescentAdultFemaleHumansMaleOncogene Proteins, FusionPyrazolesALK protein, humanAminopyridinesAnaplastic Lymphoma KinaseLactamsLactams, MacrocycliclorlatinibOncogene Proteins, FusionPyrazolesALK fusionlorlatinibneurological toxicitypseudosarcomatous myofibroblastic proliferation

Identifiers

PMID41273779
PMCPMC12677924

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.